Misplaced Pages

Minodronic acid

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Not to be confused with mildronate or medronate.
Minodronic acid
Names
Preferred IUPAC name pyridin-3-yl)ethane-1,1-diyl]bis(phosphonic acid)
Other names Minodronate; YM 529
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
IUPHAR/BPS
PubChem CID
UNII
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C9H12N2O7P2/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18)Key: VMMKGHQPQIEGSQ-UHFFFAOYSA-N
SMILES
  • O=P(O)(O)C(O)(P(=O)(O)O)Cc1cnc2ccccn12
Properties
Chemical formula C9H12N2O7P2
Molar mass 322.150 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). ☒N verify (what is  ?) Infobox references
Chemical compound

Minodronic acid is a third-generation bisphosphonate drug. It is approved for use in Japan for the treatment of osteoporosis. Its mechanism of action involves inhibition of farnesyl pyrophosphate synthase activity.

References

  1. Shridhar Hegde and Michelle Schmidt (2009). "To Market, To Market - 2009. 16. Minodronic acid". Annual Reports in Medicinal Chemistry. 45: 509–510. doi:10.1016/s0065-7743(10)45028-9.
  2. Sorbera, L.A.; Castañer, J.; Leeson, P.A. (2002). "Minodronic Acid". Drugs of the Future. 27 (10): 935–941. doi:10.1358/dof.2002.027.10.701186.
Drugs for treatment of bone diseases (M05)
Bisphosphonates
Bone morphogenetic proteins
Other
Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it.

Categories: